Kenvue (NYSE:KVUE) Sets New 52-Week High – Should You Buy?

Kenvue Inc. (NYSE:KVUE) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $23.57 and last traded at $23.39, with a volume of 4794998 shares changing hands. The stock had previously closed at $23.04.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on KVUE. UBS Group lifted their target price on Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Citigroup dropped their target price on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Bank of America lifted their price target on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Finally, Royal Bank of Canada cut Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price on the stock. in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $22.64.

Kenvue Stock Performance

The firm has a market cap of $44.49 billion, a price-to-earnings ratio of 39.72, a P/E/G ratio of 2.97 and a beta of 1.36. The firm’s 50 day moving average price is $22.55 and its 200-day moving average price is $20.45. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The company had revenue of $4 billion for the quarter, compared to the consensus estimate of $3.93 billion. During the same quarter in the previous year, the firm posted $0.32 EPS. The business’s revenue was down .3% compared to the same quarter last year. On average, analysts anticipate that Kenvue Inc. will post 1.08 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be paid a dividend of $0.205 per share. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 annualized dividend and a yield of 3.53%. Kenvue’s dividend payout ratio is 141.38%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Leo Wealth LLC lifted its holdings in Kenvue by 0.3% in the third quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after buying an additional 481 shares during the period. Massmutual Trust Co. FSB ADV boosted its holdings in shares of Kenvue by 6.2% in the third quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after buying an additional 492 shares during the period. Wolff Wiese Magana LLC increased its position in shares of Kenvue by 0.7% during the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after acquiring an additional 501 shares in the last quarter. Marathon Capital Management lifted its position in Kenvue by 0.3% in the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock valued at $2,722,000 after acquiring an additional 514 shares in the last quarter. Finally, Manchester Capital Management LLC lifted its holdings in shares of Kenvue by 80.8% in the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after purchasing an additional 530 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.